XHALE ASSURANCE® | An Xhale, Inc. Company
Assurance® – Future Products
We are applying our Assurance technology beyond conventional pulse oximetry. Currently, we are developing additional applications of our Assurance technology in order to improve and expand the use of conventional pulse oximetry in hospitals and other clinical settings to monitor critical patient parameters, as well as to increase the number of parameters which can be measured.
Assurance Multi-Sense Sensor
The unique nasal ala location of our Assurance sensors enables reporting on additional patient parameters which cannot be provided with conventional digit pulse oximetry.
We are developing a next generation sensor, our Assurance multi-sense sensor, which will be similar to our Assurance Nasal Alar SpO2 Sensor, but which will also enable the monitoring of parameters beyond pulse rate and oxygen saturation, including:
- Respiratory rate parameters
- Cardiorespiratory function parameters
- Motor activity
We believe that measuring these additional parameters is important because a low respiration rate may be indicative of respiratory depression and a high respiration rate may be indicative of patient distress, both of which are indicative of health risks, and measuring a patient’s breathing patterns can be used to detect evidence of impending drug-induced respiratory depression or of physiological conditions which can result in hypoxia.
To monitor a patient’s respiratory related parameters in addition to the patient’s pulse rate and oxygen saturation, Assurance is developing a Respiratory Oximeter.
This product candidate consists of a specialized adapter cable that contains all the electronics needed to drive the host monitors, housed in a small pod on the cable. The Assurance multi-sense sensor attaches at one end of the Respiratory Oximeter cable, which in turn connects into the targeted host monitor.
Respiration-related parameters are not among the parameters measured in standard pulse oximetry. Monitoring respiration-related parameters is important because a low respiration rate may be indicative of respiratory depression and a high respiration rate may be indicative of patient distress, both of which are indicative of health risks.
Assurance® PCA Guardian
Most patients in the hospital are on some form of intravenous drug therapy, and many post-operative patients are on intravenously delivered pain medication. The interaction of drug therapy with each patient’s unique physiological and genotypic conditions is inherently risky. Currently, there is no way to effectively monitor patients who are outside the operating room and other critical care areas where patients are not intubated.
To answer this problem, Assurance® is developing the Assurance® PCA Guardian. This standalone device will enable hospitals to monitor and diagnose post-operative patients who are on intravenously delivered pain medication in areas of the hospital where patients are not generally monitored.
The Assurance® PCA Guardian will utilize an Assurance® multi-sense sensor to monitor cardiorespiratory parameters of patients who are receiving pain medication via infusion pumps. The Assurance® PCA Guardian is being designed as a small, portable device which will attach to the intravenous pole that suspends intravenous fluid bags and other small equipment next to the patient, with a small opening in the device through which the intravenous tubing will pass. In the event the patient were trending toward respiratory depression and airway obstruction, the Assurance® PCA Guardian would automatically terminate or reduce the rate of the medication infusion by pinching the intravenous tubing, obstructing the flow of pain medicine and generating an alert to notify healthcare staff. Our Assurance® PCA Guardian will not require any changes to existing infusion pumps and is being designed to be available for use on both intubated and non-intubated patients.
The Assurance product candidates discussed on this page have not received FDA marketing authorization. These product candidates are either in development or pre-development stages. Xhale is not soliciting or accepting orders for any of these product candidates.